Related references
Note: Only part of the references are listed.Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register
E. Lie et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Predicting the outcome of ankylosing spondylitis therapy
Nathan Vastesaeger et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Treatment Response, Drug Survival, and Predictors Thereof in 764 Patients With Psoriatic Arthritis Treated With Anti-Tumor Necrosis Factor α Therapy Results From the Nationwide Danish DANBIO Registry
Bente Glintborg et al.
ARTHRITIS AND RHEUMATISM (2011)
Outcomes of switching anti-TNF drugs in rheumatoid arthritis-a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN)
Liisa M. Virkki et al.
CLINICAL RHEUMATOLOGY (2011)
Efficacy in current practice of switching between anti-tumour necrosis factor-α agents in spondyloarthropathies
Julien Paccou et al.
RHEUMATOLOGY (2011)
DANBIO-powerful research database and electronic patient record
Merete Lund Hetland
RHEUMATOLOGY (2011)
Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study
Suzanne Arends et al.
ARTHRITIS RESEARCH & THERAPY (2011)
Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry
Bente Glintborg et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register
Paul A. C. Lord et al.
RHEUMATOLOGY (2010)
Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study
Antonio Spadaro et al.
RHEUMATOLOGY (2010)
Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy
Martin Rudwaleit et al.
ARTHRITIS RESEARCH & THERAPY (2010)
Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis
Guenther Haberhauer et al.
WIENER MEDIZINISCHE WOCHENSCHRIFT (2010)
Efficacy and Safety of Etanercept in Psoriasis after Switching from Other Treatments An Observational Study
Annamaria Mazzotta et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2009)
Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis
C. Lukas et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis
D. van der Heijde et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Effectiveness, Safety, and Predictors of Good Clinical Response in 1250 Patients Treated with Adalimumab for Active Ankylosing Spondylitis
Martin Rudwaleit et al.
JOURNAL OF RHEUMATOLOGY (2009)
Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry
M. L. Hetland et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
The comparative one-year performance of anti-tumor necrosis factor α drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis:: Results from a longitudinal, observational, multicenter study
Marte Schrumpf Heiberg et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2008)
Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis
L. C. Coates et al.
RHEUMATOLOGY (2008)
Switching anti-TNF therapy in ankylosing spondylitis
D. J. Pradeep et al.
RHEUMATOLOGY (2008)
Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug
K. L. Hyrich et al.
RHEUMATOLOGY (2008)
Switching tumour necrosis factor α antagonists in patients with ankylosing spondylitis and psoriatic arthritis:: an observational study over a 5-year period
Fabrizio Conti et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?
Elisabeth Hjardem et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis - Results from a large UK national cohort study
Kimme L. Hyrich et al.
ARTHRITIS AND RHEUMATISM (2007)
Predictors of response to anti-TNF-α therapy among patients with rheumatoid arthritis:: results from the British Society for Rheumatology Biologics Register
K. L. Hyrich et al.
RHEUMATOLOGY (2006)
Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: Results of a fifty-four-week study
Fabrizio Cantini et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2006)
Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis
J Zochling et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
ASAS/EULAR recommendations for the management of ankylosing spondylitis
J Zochling et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis
J Braun et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period
JJ Gomez-Reino et al.
ARTHRITIS RESEARCH & THERAPY (2006)
Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER Group
Loreto Carmona et al.
ARTHRITIS RESEARCH & THERAPY (2006)
Adalimumab (Humira®) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade®) or etanercept (Enbrel®):: results from the STURE registry at Karolinska University Hospital
MC Wick et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2005)
Routine database registration of biological therapy increases the reporting of adverse events twentyfold in clinical practice. First results from the Danish Database (DANBIO)
ML Hetland et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2005)
Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor α blockers in ankylosing spondylitis
M Rudwaleit et al.
ANNALS OF THE RHEUMATIC DISEASES (2004)
Share Paper
